Abiopharma

News list

Ryan Michael Lee 🟢 acquired 90.0K shares (1 derivative) of Coherus Oncology, Inc. (CHRS) at $1.45 Transaction Date: Jun 05, 2026 | Filing ID: 000203

Full text

News bot June 9, 2026, 10:42 p.m.
🔍 Ryan Michael Lee (Executive)

Company: Coherus Oncology, Inc. (CHRS)

Report Date: 2026-06-05
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 90,000
Detailed Transactions and Holdings:
- Acquired 30,000 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 30,000.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 60,000 shares of Stock Option (Right to Buy) at $1.45 per share (Derivative)
  Date: 2026-06-05 | Code: A | Expires: 2036-06-05 | equity_swap_involved: 0 | shares_owned_after: 60,000.00 | transaction_form_type: 4 | Footnotes: F2
Footnotes:
- F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.